Effect of anticoagulant therapy on the hypercoagulable state in patients carrying the factor V Arg506Gln mutation

Thrombosis Research

Volumn 92, Issue 4, 1998, Pages 157-162

  Larsen, Torben B ^a,c   Lassen, Jens F ^a   Dahler Eriksen, Bjarne S ^a   Petersen, Per Hyltoft ^b   Brandslund, Ivan ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Anticoagulants; APC resistance; Factor V

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGININE; BLOOD CLOTTING FACTOR 5; FIBRINOGEN DEGRADATION PRODUCT; GLUTAMINE; PHENPROCOUMON; PROTHROMBIN; WARFARIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERCOAGULABILITY; ORAL DRUG ADMINISTRATION; POINT MUTATION; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARGININE; CASE-CONTROL STUDIES; FACTOR V; FEMALE; GLYCINE; HUMANS; IMMUNOENZYME TECHNIQUES; LINEAR MODELS; MALE; MIDDLE AGED; PHENPROCOUMON; POINT MUTATION; POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; WARFARIN;

EID: 0032533768     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00123-6     Document Type: Article

References (24)

1. Dahlbäck B. New molecular insights into the denetics of thrombophilia. Thromb Haemost. 74:1995;139-148.
2. Koster T., Rosendaal F.R., de Ronde H., Briet E., Vandenbroucke J.P., Bertina R.M. Venous thrombosis due to poor anticoagulant response to activated protein C. Leiden thrombophilia study Lancet. 342:1993;1503-1506.
3. Dahlbäck B., Carlsson M., Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Prediction of a cofactor to activated protein C Proc Natl Acad Sci USA. 90:1993;1004-1008.
4. Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H., van der Velden P.A., Reitsma P.H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
5. Zöller B., Berntsdotter A., Garcia de Frutos P., Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 85:1995;3518-3523.
6. Larsen T.B., Lassen J.F., Brandslund I., Byriel L., Bruun Petersen G., Nørgaard-Pedersen B. The Arg506Gln mutation (FV Leiden) among a cohort of 4188 unselected Danish newborns. Thromb Res. 89:1998;211-215.
7. Ridker P.M., Hennekens C.H., Lindpaintner K., Stampfer M.J., Eisenberg P.R., Miletich J.P. Mutation in the gene coding for coagulation fact or V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 332:1995;912-917.
8. Halbmayer W.M., Haushofer A., Schon R., Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis. 5:1994;51-57.
9. Svensson P.J., Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 330:1994;517-522.
10. Voorberg J., Roelse J., Koopman R., Buller H., Berends F., ten Cate J.W., Mertens K., van Mourik J.A. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 343:1994;1535-1536.
11. Leroy-Matheron C., Levent M., Pignon J., Mendonca C., Goualt-Heilmann M. The 1691G〉A Mutation in the factor V gene. Relationship to activated protein C (APC) resistance and thrombosis in 65 patients Thromb Haemost. 75:1996;4-10.
12. Zöller B., Holm J., Svensson P.J., Dahlbäck B. Elevated levels of protrombin activation fragment 1+2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inhertied protein S deficiency. Thromb Haemost. 75:1996;270-274.
13. Simioni P., Scarano L., Gavasso S., Sardella C., Girolami B., Scudeller A., Girolami A. Prothrombin fragment 1+2 and trombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Br J Haematol. 92:1996;435-441.
14. Greengard J.S., Eichinger S., Griffin J.H., Bauer K.A. Brief report. Variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg→Gln mutation in the gene for factor V N Engl J Med. 331:1994;1559-1562.
15. Catto A., Carter A., Ireland H., Bayston T.A., Lane D.A., Grant P.J. Factor V Leiden mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol. 15:1995;783-785.
16. van den Burg P.J.M., Hospers J.E.H., van Vliet M., Mosterd W.L., Bouma B.N., Huisveld I.A. Changes in haemostatic factors and activation products after exercise in healthy subjects with different ages. Thromb Haemost. 74:1995;1457-1464.
17. Brandslund I., Dahler-Eriksen B., Lassen J.F., Dahler-Erikson K., Larsen T.B. Change from phenprocoumon to warfarin. sceme and program for monitoring and dose adjustment Thromb Haemost. 75:1997;702-703.
18. Zöller B., Svensson P.J., He X., Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 94:1994;2521-2524.
19. Zöller B., He X., Dahlbäck B. Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease. Thromb Haemost. 73:1995;743-745.
20. Bland M. An Introduction to Medical Statististics. 2:1985;Oxford University Press, Oxford. p. 363.
21. Kyrle P.A., Eichinger S., Pabinger I., Stümpflen A., Hirschl M., Bialonczyk C., Schneider B., Mannhalter C., Melichhart M., Traxler G., Weltermann M., Speiser W., Lechner K. Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism. Thromb Haemost. 77:1997;829-833.
22. Tripodi A., Cattaneo M., Molteni A., Cesana B.M., Mannucci P.M. Changes of protrombin fragment 1+2 (F1+2) as a function of increasing intensity of oral anticoagulation. Thromb Haemost. 79:1998;571-573.
23. Baglin C., Brown K., Luddington R., Baglin T. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FV R506Q) mutation. Effect of warfarin and prediction by precipitating factors Br J Haematol. 100:1998;764-768.
24. Sarasin F., Bounameaux H. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis. BMJ. 316:1998;95-99.